Life Extension Magazine

Life Extension Magazine November 2012

Report

Innovative Laser Therapy Offers New Hope for Breast Cancer Patients

By Logan Bromwell

Lab Studies Provide Dramatic Results

Laser-assisted immunotherapy has received compelling validation in the laboratory. When rats with experimentally induced breast cancer were subjected to the treatment, they experienced marked increases in survival rates.11 In addition, researchers have documented the eradication of both primary tumors and metastases.11,16 Most importantly, successfully treated rats have proven to be resistant to developing new tumors—even when cancer cells were directly injected into the animals' bodies.4,11

For the pre-clinical experiments, rats were injected with breast cancer cells, which formed localized primary tumors.3,4 After 11 days, the animals were treated with the laser therapy with the indocyanin green or laser therapy with indocyanin green and the immune booster described above.

In the group of untreated animals, the primary tumors grew rapidly within the first month, and all animals died by 40 days. The treated animals, on the other hand, had only modest growth of the primary tumor, which then proceeded to shrink in size—and 38% of the animals survived until the end of the study at 120 days (Figures 1 and 2).4 Only animals administered the three-prong combination achieved long-term survival. In other words, the 38% of the animals that survived until the end of the study all received the full laser-assisted immunotherapy that included indocyanin green and the immune enhancement adjuvant.

The most dramatic result—and the one with the greatest potential impact for people with breast cancer—was the effect on metastases. The untreated animals developed multiple metastases in the groin (inguinal) and armpit (axillary) areas.3,4 In the treated group, however, the metastases were completely destroyed within 40 days (Figure 3).

Human Breast Cancer Study Results: 80% Survival Rate for Stage IV Cancer

Energized by the striking results from the animal studies, a group called the International Strategic Cancer Alliance decided to bring the benefits of laser-assisted immunotherapy to women with breast cancer. This malignancy is expected to cause over 290,000 new cases this year in the US and affects millions of women who battle with recurrence and remissions.2 It is a significant cause of death, disfigurement, and disability.

Figure 1 Survival of Rats with Breast Cancer

After injection with breast cancer cells on day zero, untreated animals begin dying by day 30, and all are dead by day 40. But tumor-bearing animals treated with laser-assisted immunotherapy survived much longer and many were still alive by the end of the study.4

Figure 2 Size of Primary Breast Cancer

In an untreated animal, death occurred on day 32, following rapid growth of the primary breast cancer. The primary tumor grew much more slowly in a treated animal, peaked at about 30 days, and then gradually disappeared, becoming undetectable by day 65.4

The researchers were determined to evaluate the laser-assisted immunotherapy as soon as possible. Frustrated with the corrupt, inefficient, and time-consuming ways of the FDA—the all-powerful agency that regulates such research in the US—they chose a highly regarded private clinic in the Caribbean as the venue for their study.3

Because of the technique's unique ability to destroy both an advanced primary tumor and life-threatening metastases, the researchers decided to treat women with breast cancers that had already spread to the lymph nodes or to other parts of the body. Although the study was opened to 45 women, the following is a preliminary report on the first 15 subjects enrolled.

The study protocol was similar to that used in the animal studies described above. Subjects received two courses of treatment over two weeks, and were followed for one year. If needed, an additional course of treatment was available.

After a physical examination and blood testing, the women received an injection of a local anesthetic in the area of the primary breast cancer, followed by injection of the photosensitizing agent (indocyanin green) into the tumor. Next, the near-infrared laser was applied to the area in and around the tumor. During this phase, the laser destroyed cells in the primary superficial tumor, while exposing their biological markers to the subject's immune system.

After 10 to 12 minutes of laser therapy, the immune-boosting material was injected around and underneath the tumor. In this phase of the treatment, the subject's own immune system cells were drawn to the tumor area to attack the primary breast tumor, as well as the malignant cells in lymph nodes and metastases in other parts of the subject's body.

The results from this early study are encouraging, particularly in light of established rates of survival. Among all 15 subjects in the study, 80% remain alive today. Compare that with the typical survival rate in the United States for women with such advanced breast cancer, which is only 23.8% at 5 years.17 (This study is so new that no woman has yet reached the 5-year milestone.)

At the time of this writing, the women in the laser-assisted immunotherapy study had an average survival of more than 29 months after treatment, and still counting. Results of conventional chemotherapeutic or anti-hormone breast cancer treatment aren't nearly as encouraging. One study reported an average survival of just 15.4 months,18 another small study reported survival up to 23.1 months, but had no survivors by 3 years.19

Tales of Courage and Survival

Of course, compelling as they might be, numbers tell only a portion of any story about human health and longevity. The real picture of the treatment's potential comes from the real-life stories of the women who participated in this study. Here are just a few of those stories.

A 66-year-old woman enrolled in the study in August 2008, after having only a modest response to eight cycles of conventional chemotherapy. At the time of her enrollment, her disease had progressed to stage IV, with at least one metastasis as diagnosed with a PET/CT scan. She received one full laser-assisted immunotherapy treatment in December 2008. A follow-up PET/CT scan showed disappearance of the primary tumor, and no new metastases or lymph node involvement.

Figure 3 Size of Breast Cancer Metastases

Left Microscopic Image of Breast Carcinoma.

Right Metastatic tumors in an untreated animal rapidly grew in size, culminating in the animal’s death on day 30. By contrast, those in the treated animal grew modestly, peaked at about day 32, and then rapidly regressed. No metastases were detected after day 40 in the treated animal, which survived to the end of the study.4

One year and nine months after the treatment, this patient received the following mammography report: "The result of your breast imaging exam shows no evidence of cancer."

She remains disease-free at more than 3 years and 4 months following treatment.

A 78 year-old woman with stage IV breast cancer, who had received no conventional treatment, enrolled in the study in January 2009. After undergoing the laser-assisted immunotherapy, a follow-up PET/CT scan revealed no visible cancer and no metastases. She did experience a brief recurrence of the tumor, but that condition resolved without further therapy.

More than 3 years later, she too remains disease-free.

Important Facts about Breast Cancer

According to the National Cancer Institute:

  • There are more than 2.75 million living women with a history of breast cancer, including those with active disease and those who have been cured.24
  • One in eight women (12.38%) born today will be diagnosed with breast cancer at some time in their lives.25
  • 5.72% of women will develop cancer of the breast between their 50th and 70th birthdays.25
  • The median age at diagnosis for breast cancer is 61 years old (Figure 4).26
  • The median age of dying from breast cancer is 68 years old (Figure 4).26
  • Overall 5-year survival for women with breast cancer is 90.3%. For those with cancer that has metastasized (stage IV), however, just 23.8% (or fewer) remain alive 5 years after their diagnosis.27
  • There has been a fluctuating trend in breast cancer incidence since 1975 (Figure 5).

Two women with earlier stage cancers (stage II) entered the study in 2009; one had received some conventional therapy while the other had none. Following laser-assisted immunotherapy, both subjects remain alive and disease-free today.

These cases show the great potential of laser-assisted immunotherapy in treating breast cancer. No therapy is perfect, however, and it's important to note that not all of the women in the study experienced the same results as the ones mentioned above.

For example, a 65-year-old woman with stage IV breast cancer enrolled in the study in August 2008, after a number of failures of conventional therapy. She did experience some tumor recurrence requiring surgery 15 months after her initial laser treatment, but survived until 3 years and 3 months after the start of the study. The experimental treatment may have prolonged her life, but there is no way to be certain.

Figure 4 Ages at Diagnosis and Death from Breast Cancer

Breast cancer can occur as early as the late 20s, but diagnoses peak by about age 60 (blue bars). Rates of death from breast cancer rise sharply between early middle age, and remain high well into advanced years (red bars).26

Figure 5 Trend in Breast Cancer Deaths

Rates of death from breast cancer have fluctuated since the mid-1970s. Points above the zero line indicate periods of increased death rates; points below the line indicate periods of declining death rates.26

Summary

Laser-assisted immunotherapy is a promising new weapon in the war on cancer. The results of this study so far show 80% of the participants still alive today compared to the typical 5-year survival rate in the US of only 23.8% for advanced breast cancer. Providing a non-toxic therapy that supports and stimulates rather than destroys the body's best defense arsenal, the immune system, is a monumental gain against the tenacious and formidable opponent known as cancer.

Of particular significance is the lack of serious side effects caused by laser-assisted immunotherapy. Even lumpectomies can result in significant mutilation to the affected breast, while follow-up radiation, chemotherapy and hormone-blocking agents result in debilitating initial side effects and deadly long-term toxicities.

For example, in a report released last month that studied 12,000 breast cancer survivors, there was a 470% increased risk of developing heart failure in the group receiving chemotherapy compared to breast cancer patients who did not undergo chemotherapy.20 The cancer establishment considers those treated with chemotherapy to be successes if they survive the cancer, but conveniently ignores the fact that the treatment causes heart failure.

The objective of laser-assisted immunotherapy is to eradicate the primary tumor along with metastatic lesions without inflicting the side effects associated with conventional breast cancer treatment.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.

For more information regarding the availability of the laser-assisted immunotherapy for breast cancer, please call International Strategic Cancer Alliance at 888-868-2981.

Creating a Customized Cancer Vaccine

Developing an effective anti-cancer vaccine has been the goal of oncology for decades.21,22 The idea is to identify one or several markers, or antigens, borne only by tumor cells, for use in the manufacture of a vaccine. In theory, such a vaccine could eliminate cancer once and for all.22 The vaccine could even be beneficial for those with existing cancers, as the vaccine could expedite destruction of the existing tumor by activating the immune system.

However, like most attempts at a “one-size-fitsall” strategy, this approach has flaws that limit its appeal. Often what appears to be a single tumor actually contains multiple different cell lines, each bearing a unique marker, and each affecting patient survival differently.23 A cancer vaccine prepared in a laboratory therefore has essentially zero chance of raising an immune response to every cell type in any one person’s tumor, allowing a few to survive and produce cancer recurrences.

This situation is quite similar to the well-known annual quandary of flu vaccine manufacturers. Based on the best available information about the previous year’s flu virus, they must make an educated guess about which specific viral components to include in the upcoming year’s vaccine (e.g., H1N1, H5N1, etc). Most years they are successful, but occasionally a virus appears for which we are entirely unprotected.

Laser-assisted immunotherapy eliminates this kind of guesswork. That’s because the “vaccine” is manufactured within each individual person’s body, in response to their own unique tumor markers. This customized vaccine can then direct all of the immune system’s powerful resources to eliminating the existing cancer, at the same time producing persistent immunity against future recurrences.14

References

1. Frieden TR, Myers JE, Krauskopf MS, Farley TA. A public health approach to winning the war against cancer. Oncologist. 2008 Dec;13(12):1306-13.

2. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed September 4, 2012.

3. Adalsteinsson O. Laser-Assisted Immunotherapy: A Novel Autologous Vaccine Strategy for Cancers with Solid Tumors Clinical Protocol #ISCA 0001 ed.: International Strategic Cancer Alliance; 2012.

4. Chen WR, Zhu WG, Dynlacht JR, Liu H, Nordquist RE. Long-term tumor resistance induced by laser photo-immunotherapy. Int J Cancer. 1999 May 31;81(5):808-12.

5. Chen WR, Huang Z, Korbelik M, Nordquist RE, Liu H. Photoimmunotherapy for cancer treatment. J Environ Pathol Toxicol Oncol. 2006;25(1-2):281-91.

6. Chen WR, Liu H, Ritchey JW, Bartels KE, Lucroy MD, Nordquist RE. Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats. Cancer Res. 2002 Aug 1;62(15):4295-9.

7. Chen WR, Liu H, Carubelli R, Nordquist RE. Synergistic effect of photothermal and photoimmunological reactions in treatment of metastatic tumors. J Xray Sci Technol. 2002 Jan 1;10(3):225-35.

8. Canti G, Calastretti A, Bevilacqua A, Reddi E, Palumbo G, Nicolin A. Combination of photodynamic therapy + immunotherapy + chemotherapy in murine leukiemia. Neoplasma. 2010;57(2):184-8.

9. Wainwright M. Photodynamic therapy: the development of new photosensitisers. Anticancer Agents Med Chem. 2008 Apr;8(3): 280-91.

10. Stefflova K, Chen J, Zheng G. Killer beacons for combined cancer imaging and therapy. Curr Med Chem. 2007;14(20):2110-25.

11. Chen WR, Adams RL, Carubelli R, Nordquist RE. Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment. Cancer Lett. 1997 May 1;115(1):25-30.

12. St Denis TG, Aziz K, Waheed AA, et al. Combination approaches to potentiate immune response after photodynamic therapy for cancer. Photochem Photobiol Sci. 2011 May;10(5):792-801. Epub 2011 Apr 9.

13. Chen WR, Korbelik M, Bartels KE, Liu H, Sun J, Nordquist RE. Enhancement of laser cancer treatment by a chitosan-derived immunoadjuvant. Photochem Photobiol. 2005 Jan-Feb;81(1):190-5.

14. Garg AD, Nowis D, Golab J, Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis. 2010 Sep;15(9):1050-71.

15. Chen WR, Carubelli R, Liu H, Nordquist RE. Laser immunotherapy: a novel treatment modality for metastatic tumors. Mol Biotechnol. 2003 Sep;25(1):37-44.

16. Chen WR, Jeong SW, Lucroy MD, et al. Induced antitumor immunity against DMBA-4 metastatic mammary tumors in rats using laser immunotherapy. Int J Cancer. 2003 Dec 20;107(6): 1053-7.

17. Beinart G, Gonzalez-Angulo AM, Broglio K, et al. Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival. Clin Breast Cancer. 2007 Dec;7(11):867-74.

18. Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol. 2007 Dec;14(12):3345-51.

19. Cummiskey RD, Mera R, Levine EA. Preoperative chemotherapy for locally advanced breast carcinoma at Charity Hospital, New Orleans, Louisiana. Am Surg. 1998 Feb;64(2):103-6.

20. Available at: http://vitals.nbcnews.com/_news/2012/08/31/13573426-breast-cancer-survivors-may-face-second-threat-heart-failure?lite. Accessed September 4, 2012.

21. Tan PH, Lota AS. Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics. Expert Opin Pharmacother. 2008 Oct;9(15):2639-60.

22. Watson CJ, Gusterson BA. A prophylactic vaccine for breast cancer? Breast Cancer Res. 2010;12(4):310.

23. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 Mar;11(3):259-73.

24. Available at: http://seer.cancer.gov/statfacts/html/breast.html#prevalence. Accessed April 5, 2012.

25. Available at: http://seer.cancer.gov/statfacts/html/breast.html#risk. Accessed April 5, 2012.

26. Available at: http://seer.cancer.gov/statfacts/html/breast.html#incidence-mortality. Accessed April 5, 2012.

27. Available at: http://seer.cancer.gov/statfacts/html/breast.html#survival. Accessed April 5, 2012.